– CANADA, Calgary – Zenith Capital Corp. (OTC: ZHCLF) today announced the appointment of Dr. Brad Thompson (Ph.D.) to its board of directors.
“We are very pleased to welcome Dr. Thompson to our Board of Directors, a deeply experienced biotech businessperson who brings a wealth of varied experience, which will assist in further advancing Zenith,” said CEO, Donald McCaffrey.
Concurrently, Dr. Eldon Smith stepped down from the Board of Directors, effective today.
About Dr. Brad Thompson
Dr. Thompson is an experienced biotechnology founder and executive having served as a public company CEO for 22 years. He has served as Chairman, Director, and an Audit Committee member on a number of public company (NASDAQ, TSX and CDNX) boards of directors, and has served as a Director of private company boards and industry groups (including Chairman and Chairman Emeritus of BIOTECanada). He has taken companies public on the TSX, NASDAQ and former Alberta Stock Exchange, as well as led successful cross-listings (from the TSX to the NASDAQ).
“I am thrilled to be joining Zenith at such an exciting time in the clinical development of its lead compound ZEN-3694,” said Dr. Thompson. “With such a broad clinical program offering, including multiple promising opportunities to improve the lives of oncology patients, I am looking forward to seeing what comes next from this impressive program.”
Dr. Thompson holds a Ph.D. in Microbiology and Immunology from the University of Western Ontario. Before entering the private sector, his research affiliations included working with NASA and the Canadian Space Agency, the United Nations, Colorado State University, and the University of Alberta.
About Zenith
Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for various oncologic indications, specifically: mCRPC in combination with androgen receptor inhibitor, XTANDI; Triple Negative Breast Cancer in combination with the PARP inhibitor TALZENNA; Androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI; Ovarian cancer in combination with immune-checkpoint inhibitors, nivolumab, and ipilimumab; NUT midline carcinoma in combination with chemotherapy; solid tumors and lymphoma in combination with entinostat.
For more information: https://www.zenithepigenetics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.